Thyrocare Technologies Ltd IPO Message Board (Page 74)

ttl gmp 90-120 app 850-900

Absolutely bogus

Can someone please help me out.

I do have my account with internet banking in SBI and option of ASBA is also there. But, I do have my demat account with some other broker and I want to apply online for IPO and recieve the money immediately when I sell it in my SBI''s account which is currently not linked to any demat account. For this reason is it necessary for me to open trading account with SBI or only Demat account is sufficient.

Thanks in advance.

If you want to get the sale proceeds back into the same account from which IPO was subscribed through ASBA then you have to open a 3 in 1 account.
This you can do it in any bank which has also securities trading arm such as SBI, HDFC, ICICI etc.

Ok. Thank you @CLD

Ahmedabad Kostak

Thyrocare - 1050 (Started buying)
Ujjivan - 900 (Low buying)

True this ... “In the short run, the market is a voting machine but in the long run, it is a weighing machine.” ― Benjamin Graham

Thyrocare GMP 204 - 207 (Stable; low volumes)
Ujjivan GMP 39 - 41 (Stable; low volumes)

All Grey Market Operators are busy in a Wedding at Delhi

@eagleye gmp crash ttl 90-120 and ujjivan 25-35

My information is absolutely rock solid genuine ... please go recheck at your side :)~

Thanks Septa sir.

Application ka Kostak price batao

Septa sir I have some queries mentioned in 248.8 I will be very thankful pl z reply my some of the tax related issue.. Thanks in advance .

@Uchitji, thanks for the . Good for listing gains but risky for medium term until proper price discovery post listing.

@Septaji, I agree with ur assertion that TTL offers good MoS wrt Dr Lal. But my point is that we may be taking Dr Lal''s pricing for granted. TTL is diversifying into water testing/other growth areas & I like Velumani very much! but still to justify PE 40 it needs to achieve a 40% EPS growth going forward which remains sufficiently uncertain IMO. By the same token, Dr Lal would require an insanely high growth in future to sustain its price in future. We are taking position when the Diagnostics sector has no apparent potential for further re-rating on ''up side''. Any re-rating in future, if at all, would be on downside. So, only sophisticated investors who can actually track these developments & act proactively should think for MT/LT commitments. But for the hoi-polloi, like myself, it''s better to get off the ship at first sight of danger i.e. either flip or keep a strict moving stop-loss.

I just noticed ur message in the trail, Septaji. Good to see that ur alerted to a downward re-rating possibility. Afterall we would be betting on someone else''s bet.

i agre 100% with u and Uchit sometime it is useless to follow fundamental but same time have ur stop loss and enjoy the market rally

Parag Milk IPO:-
Issue Size: 1000 cr.
Issue Opens: 4th May 
Issue Closes: 6th May

Price band: 328-356 ( Expecting)
Lot 42 & Multiple 

No Retail Discount
BRLM: Kotak

Retail Allocation 10%
Financials:-
Nav Rs 28
EPS Rs 7 FY15
EPS Rs 8.4 FY 16 ( Non Diluted)
PE 43-46x
Share Capital 15 Cr.
Debt & Loan 500 Cr.

Listed Peer
Hatson Agro
PE 70x

Prabhat Dairy
PE 90x

looks a bit costly although i guess this isn''t the final price.

Can anyone tell me, can two person apply for an ipo from for a single demat a/c ?

No

I am not understanding what''s unique in Dr. Lal and Throcare business model. They are enjoying very high valuation. Business they are running is simple and no rocket science is involved. Both are available at high P/E. I remembered late 90''s when Microsoft, Cisco, Intel enjoying no. one position in their business segment with robust growth but still not over valued.

I talked to many doctors they told me pathology business is not making good money. This is the main reason 75 to 80 percent multi speciality hospitals outsourced pathology department to third party.

I think we need to book profit on Dr. Lal and exit on Thyrocare after listing gain.

the Stock Market, in short term is a voting machine, in the long term is a weighing machine

very true

ok septa sir now undestood ujjivan return on equity 20 percent and bv 94 so hdfc bank roe 20 and price to b.v 4 so same apply to ujjivan 94 multiply by 4 give fair value ?

how much is maximum qty of shares retail can apply & upto what value?? is 2 lac a cu off limit to apply by retails customer ?

Hi to all.

I got a query.

Can we subscribe to thyrocare and ujjivan IPO.

Please post your valuable suggestions.
When I gone through financial of thyrocare it sounds good.what about its price?

Looking forward for revert.

Parag Milk IPO:-
Issue Size: 1000 cr.
Issue Opens: 4th May
Issue Closes: 6th May

Price band: 328-356 ( Expecting)
Lot 42 & Multiple

No Retail Discount
BRLM: Kotak

Retail Allocation 10%
Financials:-
Nav Rs 28
EPS Rs 7 FY15
EPS Rs 8.4 FY 16 ( Non Diluted)
PE 43-46x
Share Capital 15 Cr.
Debt & Loan 500 Cr.

Listed Peer
Hatson Agro
PE 70x

Prabhat Dairy
PE 90x

PARAG MILK FOODS LIMITED
(Refer Page Nos. 102 & 103 of DRHP dated 30th Sept’15)

FY14-15:
Diluted EPS – Rs.4.90
Return on Net Worth – 23.79%
Net Asset Value – Rs.28.07

Septa Sir,
I have L&T Finance Holdings. I purchased at Rs. 60/- now it is at Approx Rs. 70/-.
Please advice shall I book profit or hold? Thanks in advance.

L&t finance is the worst company evr seen. Hardly it moves............I bought it wn it was 73. And hardly I got chance too book profit.............kindly book profit and shift to some other companies.... Otrwice if it goes to ur purchase level anyhow it wil tak several yrs to cm to dis level...u r lucky broo

Rahool the present upside in L&T finance is that it is looking for back door entry into banking licence and IDBI and l &T finance could merge and become a private public bank however this may or may not happen so i would have a strict stop loss at 70 and move forward if the news comes then big upside if does not big fall.

I am holding this stock i have booked half my profit and on the other half i have put a stop loss of 65 as my purchase price is approx 50 and since i sold half at 70 plus my actual present holding is at 30

What is the basis of allotment in NII catrgory in case of oversubscription? Plz reply

Parag Milk Foods Limited ...

Price band Expected 325 - 350 ... i.e. PE of 100X (trailing FY15)


Refer page 63 of DRHP ...
(5) Our Company in consultation with the Investor Selling Shareholders and the BRLMs, may offer an Employee Discount of up to [●]% (equivalent of ` [●]) per Equity Share and Retail Discount of up to [●]% (equivalent of `[●]) per Equity Share, which shall be announced at least five Working Days prior to the Bid/ Issue Opening Date.

Interesting ...

EAGLEYE MULTIPLY ITS BOOK VALUE 70 BY RETURN ON NET WORTH 13 EQUALS FAIR VALUE 910

Mehul u r CA as u have mention in this forum what non sense r ur talking

You cannot take book value just by itself either take PB or PE for valuation if i take just book value and multiple that with RONW or ROE will get non sense garbage in garbage out kind of data example tata steel book value is 650 return on equity is 3% this quarter then share price should be 1950 fair price according too however u can compare P/B and ROE or RONW individual to get a picture abt the company and get a fair value individual not multiply again
P/B is an equity valuation ratio that compares market value (stock price, per share) to book value (equity of shareholders). P/B is expressed as a multiple – how many times book value stock investors are willing to pay to acquire a company''s stock. Book value is a calculation of the company''s recorded assets minus the liabilities shown on its balance sheet – a per-share estimate of the liquidation value of the company.

The straightforward calculation of P/B is:
P/B ratio = stock price / shareholders'' equity per share
The per-share equity figure is arrived at by looking at the company''s most recent balance sheet and dividing shareholders'' equity by the number of outstanding shares.

ROE or RONW is a metric of profit efficiency, an equity valuation that measures profitability as a function of the amount of capital invested by stockholders. This metric provides a percentage assessment of the return on that equity investment. ROE is calculated by dividing a company''s net income by total shareholders'' equity. RONW is calculated by dividing a company''s income by net worth

It''s useful to consider P/B ratio evaluation along with ROE & RONW evaluation. Neither valuation tool is flawless, so it''s helpful to check one valuation against another. P/B and ROE or P/B and RONW evaluate a stock from different viewpoints, but they are related; they both factor in the book value of equity. A high P/B ratio stock commonly has a correspondingly high ROE & RONW, since investors are inclined to pay higher multiples of book value for a stock that is showing them a good return. Companies with high growth rates are likely to have high P/B ratios. Divergence between the two measures, high P/B with a low ROE, can be a warning signal that shareholder equity is no longer increasing.

A good investing approach to evaluation is to combine measures, such as P/B and ROE & RONW, and to look at trends of the figures over a period of years.


However there is no accounting formula of multiple PB with ROE or RONW
since one is percentage and another is number
even mathematical if i multiple the formula
70 @ 13% i get Rs 9 which does not make
just an example how wrong is ur assumption i will give u practical example